SCIENCE
Publications & presentations
Context-Dependent Translation Inhibition as a Novel Cancer Therapeutic Modality
January 9, 2025
Interdict releases proof-of-concept pre-print study demonstrating the ability to design, synthesize, and characterize context-dependent human translation inhibitors, called Interdictors™, as a novel cancer therapeutic modality.
View publication
Sequence-Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality
May 30, 2025
Interdict’s CEO Larry Hamann presents today at the Dana Farber Targeted Degradation Webinar Series an overview of our scientific platform and pipeline efforts.
View presentation